Join us at the Genome Editing & Advances in Transgenic Technology USA Congress in Boston, MA, May 10-11. Don’t miss our presentation, "Humanized Animal Models Customized for Discovery of Disease Biology", at 2:50pm on May 10th. Come find out how we build designer genomes for our clients. Learn about our methods to create precision deletions with oligonucleote donor homology ("trueDEL nulls"), make fluorescent protein insertions via PCR product ("KRISPR-sdm"), and how to use transgenics platforms to discover pathogenicity in clinical variants ("RediMODEL"). Please contact us for attendance discounts.
In continuing collaboration with NemaMetrix, Knudra Transgenics showcases the integrated platform at ACSB meeting.
ACSB is a premier meeting for revealing the latest details in various fields like cancer biology to understanding the latest imaging techniques. At ACSB, we will showcase Knudra's capacity to build animal models and how this is evolving towards providing animal model kits for rapid discovery of biology on your favorite gene. Come see how RediMODEL and ScreenChip systems can be used to Accelerate your Science.
Knudra and NemaMetrix are bringing their advances in genome editing technology and phenotype discovery to SfN in San Diego November 12-16. Stop by the booth 1530 see the technology in action. Discover how a model organism can help your research. Visit the exhibit 9:30 a.m.-5 p.m. Sunday-Wednesday enter near hall D of the convention center.
DUBLIN, Ireland, and SALT LAKE CITY, Utah, November 2nd, 2016 (business-wire)1 - ERS Genomics Ltd and Knudra Transgenics, a leader in model-organism bioengineering, announced today a non-exclusive license agreement which provides Knudra with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering of model organisms. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.
Under the license Knudra scientists will use CRISPR technology to engineer C. elegans (commonly known as nematodes or roundworms) and D. rerio (commonly known as zebrafish) to build custom models and develop related products for their customers. Both organisms are used widely as powerful platforms for medical discovery and drug development in both basic research and the pharmaceutical and biotechnology industry.
“Knudra is a young and energetic group of highly-skilled gene editing experts and we are very pleased to provide them with access to the most powerful genome engineering technology available. We believe Knudra is a great example of how a smaller company, dedicated to building platforms for medical discovery, can benefit from use of this exciting new technology. It is very important to ERS Genomics to provide broad access to the foundational technology and we are focused on enabling as many of these companies as possible to harness CRISPR-Cas9 in multiple areas,” said Eric Rhodes, CEO of ERS Genomics.
“CRISPR-Cas9 is a very powerful tool and we are excited to have gained access to this technology through ERS Genomics. We fully expect to see an enhancement to our current genome editing capabilities,” said Dr. Chris Hopkins, CSO of Knudra. “We look forward to applying CRISPR technology in our TAVASERV Transgenesis Services. We expect the resulting integration will provide significant benefits to our customers’ research needs,” commented Dr. Trisha Brock, CEO of Knudra.
Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna,( Jinek, Chylinski et al., 2012 )2, which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome editing tool.
About ERS Genomics. ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.
About Knudra. Knudra Transgenics was formed in late 2009. Since the first client project completed in early 2010, the Knudra team has been supplying researchers and private entities custom-built transgenics. Starting first in C elegans then expanding into zebrafish, Knudra has gained the experience to efficiently get clients the transgenics they need. The Knudra Team has a combined over 30 years of experience in making transgenic organisms. Knudra uses the latest advances in genome engineering to build powerful platforms of medical discovery. Knudra has transformed its passion for genome engineering into a first-in-kind contract research service. CRISPR/Cas9 expands Knudra's service capacity as mentioned in Transgenic News,3 PharmaLetter 4 and Genomeweb.5 With licensed access to CRISPR/Cas9, Knudra will be introducing RediModel as a system of humanized animal models in an easy-to-use kit format, as profiled by Outsorucing-Pharma.6
Salt Lake City, UT. — October 10, 2016. Knudra Transgenics, a genome engineering company specializing in building transgenic model organisms for research and drug discovery, has entered into a co-marketing partnership with Nemametrix Inc., a fast-growing life sciences startup that created the innovative ScreenChip System for drug screening, mutant phenotyping, and toxicological assessment.
Uniquely aligned in their mission to reinvent how diseases are researched, Nemametrix and Knudra Transgenics will work together to expand access to new markets and sales opportunities in academic and commercial labs around the world.
“We are thrilled to partner with Knudra, a company with proven technical expertise in C. elegans genome engineering as demonstrated by their groundbreaking RediModel System and RecombiREAD technologies,” said Matt Beaudet, CEO of Nemametrix. “Paired with our ScreenChip System platform, we expect this partnership will dramatically expand our reach into labs that have not traditionally used C. elegans — enabling new breakthroughs in ALS, Alzheimer’s disease, and anti-aging research with our combined capabilities.”
As part of the co-marketing partnership, Nemametrix and Knudra Transgenics will cooperate on marketing materials, research, and resources. This will include a co-presentation at the American Society for Cell Biology (ASCB) 2016 meeting entitled Whole animal data for cell biologists: extend your understanding of your genes, proteins, and pathways with accessible in vivo research. Both companies will also have shared exhibits at the ASCB meeting being held on December 3rd and the Society for Neuroscience meeting on November 12th 2016.
Potential for further marketing, sales, and co-development partnerships between Nemametrix and Knudra are in the works. “In working with Nemametrix, we expand the reach of our service platform. The research client gains access to a series of validated disease models in our easy-to-use RediModel System. Then, by analyzing the animal model on Nemametrix’s ScreenChip System, the researcher can quickly characterize the role of human disease gene polymorphisms for their contribution to disease pathogenesis. We expect the combined platform strengths wilt lead to a significant acceleration of the pace of medical research and discovery. This agreement is our first step on the path to a long and productive relationship with Nemametrix,” said Knudra’s founder Chris Hopkins. “This is an exciting period of growth the C. elegans community.”
About Nemametrix. NemaMetrix is a biotech company located in Eugene, Oregon driving discovery in animal models of human disease using C. elegans screening and phenomics. Maintaining active collaborations within the academic research community, we help provide insights into complex biological mechanisms through our core technology, which integrates microfluidics and electrophysiology.
About Knudra Transgenics. Knudra Transgenics is located in Salt Lake City, Utah and specializes in transgenesis services in C. elegans and zebrafish. From the affordably priced Inject Express service to the premium Full Build service, clients receive products that accelerate their research progress and scientific knowledge.
Knudra Transgenics is proud to announce it is the recipient of a FastTrack SBIR Award. A total of $1.6 million is provided by the National Institutes of Health to develop and optimize Knudra’s RecombiREAD reagent for zebrafish transgenesis. Critical in getting the SBIR investment, a USTAR funded TAP project provided the key preliminary data in C. elegans demonstrating RecombiREAD allows discovery of rare gene-edited animals in large populations.
In the newly funded work, Knudra will adapt the RecombiREAD reporter to become functional in vertebrates. The zebrafish model organism is the chosen vertebrate for study because it provides an easy-to-use embryo for optimizing RecombiREAD discovery. In the age of democratization of genome editing with new tools such as the CRISPR/Cas9 system, there is now a growing screening burden in finding animals that contain the changes desired in their genomes. RecombiREAD holds promise as the tool with the potential to reduce the post-microinjection screening effort by as much as 300 fold. As a result, discovery of biallelic gene insertions becomes much more likely at the downstream step of tissue biopsy verification. Users of RecombiREAD will get immense saving in their transgenesis projects because they will obtain a dramatic reduction in expensive animal husbandry.
Statements in this press release blog post are Forward Looking. Funding activities reported are supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number R44HD090831. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.